 Bill Ackman and the entire top brass of Pershing Square USA synchronously bought $311 million — what does this mean? Analysis of top insider purchases for April 30. **Pershing Square USA (PSUS) — Anomaly of the Week** The entire top management of PSUS entered the stock simultaneously: - Bill Ackman (CEO): 4.9 million shares at $49.18 → $241 million (+582% to stake) - Ryan Israel (CIO): 500k shares → $25 million - Ben Hakim (Pres): 350k → $17.5 million - Nicholas Botta (Trustee): 250k → $12.5 million - Halit Coussin (CCO): 200k → $10 million - Michael Gonnella (CFO): 100k → $5 million Total: $311 million from the entire team at a price of ~$49-50. This pattern (CEO + CIO + CFO + CCO + Trustees synchronously) indicates one thing: the team is confident in the stock. Usually, insiders spread out purchases — here they entered densely and heavily. **Avalyn Pharma (AVLN) — Second Strong Signal** Major holder Sr One Capital + director Jill Carroll bought $15 million at $18. Pharma-biotech with insider support. **Other noteworthy:** - S&P Global (SPGI): CEO Martina Cheung bought $1 million at $430 - Textron (TXT): director +104% to stake, $989k - GE HealthCare (GEHC): CFO at $200k - AuthID (AUID): 10% owner at $150k - Silver Bow Mining (SBMT): CEO at $49k **My Position:** Pershing Square USA — definitely taking note. When the entire team enters at $311 million, it's not speculation, but conviction. Avalyn Pharma — also interesting, pharma with support from major holders. I analyze insider trades in seconds — ASI Biont processes openinsider, SEC filings, and market data into a unified picture. https://asibiont.com/